Parkinson's Disease
Posted inANS Featured Pharmacology

Pharmacotherapy of Parkinson’s Disease

Introduction Parkinsonโ€™s disease (PD) is a common neurodegenerative disorder characterized predominantly by motor symptoms including bradykinesia, rest tremor, rigidity, and postural instability. These cardinal clinical features trace back to the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced dopamine levels…
sympathomimetics
Posted inANS Featured Pharmacology

Pharmacology of Sympathomimetics: Mechanisms, Clinical Applications, and Safety

Introduction to Sympathomimetics Sympathomimetic medicationsโ€”also known as adrenergic agonistsโ€”are a diverse group of pharmacological agents that mimic the physiological actions of endogenous catecholamines (e.g., norepinephrine and epinephrine) and other neurotransmitters…
parasympathomimetics
Posted inANS Pharmacology

Cholinomimetic Drugs (Cholinergic Agonists / Parasympathomimetics)

Introduction Cholinomimetic drugs (also referred to as parasympathomimetics) are agents that mimic or enhance the actions of acetylcholine (ACh), the primary neurotransmitter found at parasympathetic postganglionic nerve endings, neuromuscular junctions, and certain synapses within the central nervous system (CNS). By activating…
Cholinergic antagonists - Parasympatholytics
Posted inANS Pharmacology

Cholinergic Antagonists: A Comprehensive Guide to Parasympatholytics and Antimuscarinic Agents

Introduction Cholinergic antagonists, also known as parasympatholytics or antimuscarinic agents, are a class of drugs that block the action of the neurotransmitter acetylcholine at muscarinic receptors in the parasympathetic nervous…